Back to Search Start Over

Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.

Authors :
Zhang W
Peng Y
Qiu Y
Cheng L
Yin Y
Li Y
Zhao L
Wu X
Source :
Jornal de pediatria [J Pediatr (Rio J)] 2024 Sep-Oct; Vol. 100 (5), pp. 505-511. Date of Electronic Publication: 2024 Apr 08.
Publication Year :
2024

Abstract

Objective: Monitoring the disease status of Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis (HLH) patients is crucial. This study aimed to investigate the different strategies and outcomes of patients with EBV-HLH and re-elevated EBV-DNA.<br />Method: A retrospective analysis was conducted on 20 patients diagnosed with EBV-HLH. Clinical features, laboratory tests, treatments, plasma EBV-DNA levels, and outcomes were assessed. Three cases were highlighted for detailed analysis.<br />Results: Nine of the 20 patients had a re-elevation of EBV-DNA during treatment, and 55.5 % (5/9) experienced relapses. Patients with persistently positive plasma EBV-DNA (n = 4) and those with re-elevated EBV-DNA after conversion (n = 9) showed a significantly higher relapse rate compared to those with persistently negative EBV-HLH (n = 7) (p < 0.05). Among the highlighted cases, Case 1 exhibited plasma EBV-DNA re-elevation after four weeks of treatment without relapse, maintaining stability with the original treatment regimen, and eventually, his plasma EBV-DNA turned negative. In Case 2, plasma EBV-DNA was elevated again with a recurrence of HLH after L-DEP. Consequently, she underwent allogeneic hematopoietic stem cell transplantation and eventually achieved complete remission (CR) with negative plasma EBV-DNA. Case 3 experienced plasma EBV-DNA re-elevation after L-DEP but remained in CR, discontinuing chemotherapy without relapse.<br />Conclusion: The re-elevation of plasma EBV-DNA during EBV-HLH treatment poses challenges in determining disease status and treatment strategies. Optimal management decisions require a combination of the level of elevated EBV-DNA, the intensity of hyperinflammation, and the patient's immune function.<br />Competing Interests: Conflicts of interest The authors declare no conflicts of interest.<br /> (Copyright © 2024. Published by Elsevier Editora Ltda.)

Details

Language :
English
ISSN :
1678-4782
Volume :
100
Issue :
5
Database :
MEDLINE
Journal :
Jornal de pediatria
Publication Type :
Academic Journal
Accession number :
38604242
Full Text :
https://doi.org/10.1016/j.jped.2024.03.006